Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations

被引：21

作者：

Ninomiya, Kiichiro ^{[1
]}

Teraoka, Shunsuke ^{[2
]}

Zenke, Yoshitaka ^{[3
]}

Kenmotsu, Hirotsugu ^{[4
]}

Nakamura, Yukiko ^{[5
]}

Okuma, Yusuke ^{[6
]}

Tamiya, Akihiro ^{[7
]}

Nosaki, Kaname ^{[3
]}

Morise, Masahiro ^{[8
]}

Aokage, Keiju ^{[9
]}

Oya, Yuko ^{[10
]}

Kozuki, Toshiyuki ^{[11
]}

Sakamoto, Tomohiro ^{[12
]}

Tanaka, Kentaro ^{[13
]}

Tanaka, Hisashi ^{[14
]}

Tanizaki, Junko ^{[15
]}

Miura, Satoru ^{[16
]}

Mizutani, Hideaki ^{[17
]}

Miyauchi, Eisaku ^{[18
]}

Yamaguchi, Ou ^{[19
]}

Ebi, Noriyuki ^{[20
]}

Goto, Yasushi ^{[6
]}

Sasaki, Takaaki ^{[21
]}

Daga, Haruko ^{[22
]}

Morita, Satoshi ^{[23
]}

Yamanaka, Takeharu ^{[24
]}

Amano, Shinsuke ^{[25
]}

Hasegawa, Kazuo ^{[26
,29
]}

Imamura, Chiyo K. ^{[27
]}

Suzuki, Kenichi ^{[28
]}

Nakajima, Kazuko

Nishimoto, Hitomi ^{[30
]}

Oizumi, Satoshi ^{[31
]}

Hida, Toyoaki ^{[10
]}

Hotta, Katsuyuki ^{[32
,34
]}

Takiguchi, Yuichi ^{[33
]}

机构：

[1] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol Oncol & Resp Med, Okayama, Japan

[2] Wakayama Med Univ, Internal Med 3, Wakayama, Japan

[3] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan

[4] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan

[5] Yokohama Municipal Citizens Hosp, Dept Resp Med, Yokohama, Japan

[6] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan

[7] Natl Hosp Org Kinki Chuo Chest Med Ctr, Dept Internal Med, Osaka, Japan

[8] Nagoya Univ, Grad Sch Med, Dept Resp Med, Nagoya, Japan

[9] Natl Canc Ctr Hosp East, Thorac Surg & Oncol Dept, Kashiwa, Japan

[10] Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Japan

[11] Natl Hosp Org Shikoku Canc Ctr, Dept Thorac Oncol & Med, Matsuyama, Japan

[12] Tottori Univ, Dept Multidisciplinary Internal Med, Fac Med, Div Resp Med & Rheumatol, Tottori, Japan

[13] Kyushu Univ, Res Inst Dis Chest, Grad Sch Med Sci, Fukuoka, Japan

[14] Hirosaki Univ, Grad Sch Med, Dept Resp Med, Hirosaki, Aomori, Japan

[15] Kishiwada City Hosp, Dept Med Oncol, Kishiwada, Japan

[16] Niigata Canc Ctr Hosp, Dept Internal Med, Niigata, Japan

[17] Saitama Canc Ctr, Dept Thorac Oncol, Saitama, Japan

[18] Tohoku Univ Hosp, Dept Resp Med, Sendai, Miyagi, Japan

[19] Saitama Med Univ, Int Med Ctr, Comprehens Canc Ctr, Dept Resp Med, Saitama, Japan

[20] Iizuka Hosp, Dept Resp Oncol, Iizuka, Fukuoka, Japan

[21] Asahikawa Med Univ, Resp Ctr, Asahikawa, Hokkaido, Japan

[22] Osaka City Gen Hosp, Dept Med Oncol, Osaka, Japan

[23] Kyoto Univ, Dept Biomed Stat & Bioinformat, Grad Sch Med, Kyoto, Japan

[24] Yokohama City Univ, Sch Med, Dept Biostat, Yokohama, Japan

[25] Japan Federat Canc Patient Grp, Yokohama, Kanagawa, Japan

[26] Japan Lung Canc Alliance, Tokyo, Japan

[27] Showa Univ, Adv Canc Translat Res Inst, Tokyo, Japan

[28] Hoshi Univ, Div Appl Pharmaceut Educ & Res, Tokyo, Japan

[29] Shizuoka Canc Ctr, Div Nursing Hematol & Stem Cell Transplantat, Shizuoka, Japan

[30] Okayama Univ Hosp, Dept Nursing, Okayama, Japan

[31] Natl Hosp Org, Hokkaido Canc Ctr, Dept Resp Med, Sapporo, Hokkaido, Japan

[32] Okayama Univ Hosp, Ctr Clin Oncol, Okayama, Japan

[33] Chiba Univ Hosp, Dept Med Oncol, Chiba, Japan

[34] Okayama Univ Hosp, Ctr Innovat Clin Med, 2-5-1, Shikata-cho, Kita-ku, Okayama, Okayama 7008558, Japan

来源：

JTO CLINICAL AND RESEARCH REPORTS | 2021年 / 2卷 / 01期

关键词：

Non-small cell lung cancer; Epidermal growth factor receptor; Systematic review; Guidelines; FACTOR RECEPTOR MUTATIONS; TRIAL COMPARING GEFITINIB; TYROSINE KINASE INHIBITORS; 1ST-LINE TREATMENT; OPEN-LABEL; PHASE-III; CHEMOTHERAPY; SURVIVAL; ERLOTINIB; AFATINIB;

D O I：

10.1016/j.jtocrr.2020.100107

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Patients with NSCLC in East Asia, including Japan, frequently contain EGFR mutations. In 2018, we published the latest full clinical practice guidelines on the basis of those provided by the Japanese Lung Cancer Society Guide -lines Committee. The purpose of this study was to update those recommendations, especially for the treatment of met-astatic or recurrent EGFR-mutated NSCLC. We conducted a literature search of systematic reviews of randomized controlled and nonrandomized trials published between 2018 and 2019 that multiple physicians had reviewed indepen-dently. On the basis of those studies and the advice from the Japanese Society of Lung Cancer Expert Panel, we developed updated guidelines according to the Grading of Recommen-dations, Assessment, Development, and Evaluation system. We also evaluated the benefits of overall and progression-free survival, end points, toxicities, and patients' reported out-comes. For patients with NSCLC harboring EGFR-activating mutations, the use of EGFR tyrosine kinase inhibitors (EGFR TKIs), especially osimertinib, had the best recommendation as to first-line treatment. We also recommended the combina-tion of EGFR TKI with other agents (platinum-based chemo-therapy or antiangiogenic agents); however, it can lead to toxicity. In the presence of EGFR uncommon mutations, except for an exon 20 insertion, we also recommended the EGFR TKI treatment. However, we could not provide recommendations for the treatment of EGFR mutations with immune checkpoint inhibitors, including monotherapy, and its combination with cytotoxic chemotherapy, because of the limited evidence pre-sent in the literature. The 2020 Japanese Lung Cancer Society Guidelines can help community-based physicians to determine the most appropriate treatments and adequately provide medical care to their patients.(c) 2020 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer. This is an open access article under the CC BY-NC-ND li-cense (http://creativecommons.org/licenses/by-nc-nd/ 4.0/).

引用

页数：13

共 57 条

[1] The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV [J].

Akamatsu, Hiroaki ;

Ninomiya, Kiichiro ;

Kenmotsu, Hirotsugu ;

Morise, Masahiro ;

Daga, Haruko ;

Goto, Yasushi ;

Kozuki, Toshiyuki ;

Miura, Satoru ;

Sasaki, Takaaki ;

Tamiya, Akihiro ;

Teraoka, Shunsuke ;

Tsubata, Yukari ;

Yoshioka, Hiroshige ;

Hattori, Yoshihiro ;

Imamura, Chiyo K. ;

Katsuya, Yuki ;

Matsui, Reiko ;

Minegishi, Yuji ;

Mizugaki, Hidenori ;

Nosaki, Kaname ;

Okuma, Yusuke ;

Sakamoto, Setsuko ;

Sone, Takashi ;

Tanaka, Kentaro ;

Umemura, Shigeki ;

Yamanaka, Takeharu ;

Amano, Shinsuke ;

Hasegawa, Kazuo ;

Morita, Satoshi ;

Nakajima, Kazuko ;

Maemondo, Makoto ;

Seto, Takashi ;

Yamamoto, Nobuyuki .

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (07) :731-770

[2] Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib [J].

Ando, M ;

Okamoto, I ;

Yamamoto, N ;

Takeda, K ;

Tamura, K ;

Seto, T ;

Ariyoshi, Y ;

Fukuoka, M .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (16) :2549-2556

[3] Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma A Phase 2 Randomized Clinical Trial [J].

Arrieta, Oscar ;

Barron, Feliciano ;

Salinas Padilla, Miguel-Angel ;

Aviles-Salas, Alejandro ;

Alejandra Ramirez-Tirado, Laura ;

Arguelles Jimenez, Manuel Jesus ;

Vergara, Edgar ;

Lucia Zatarain-Barron, Zyanya ;

Hernandez-Pedro, Norma ;

Cardona, Andres F. ;

Cruz-Rico, Graciela ;

Barrios-Bernal, Pedro ;

Yamamoto Ramos, Masao ;

Rosell, Rafael .

JAMA ONCOLOGY, 2019, 5 (11)

[4] Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network [J].

Beau-Faller, M. ;

Prim, N. ;

Ruppert, A. -M. ;

Nanni-Metellus, I. ;

Lacave, R. ;

Lacroix, L. ;

Escande, F. ;

Lizard, S. ;

Pretet, J. -L ;

Rouquette, I. ;

de Cremoux, P. ;

Solassol, J. ;

de Fraipont, F. ;

Bieche, I. ;

Cayre, A. ;

Favre-Guillevin, E. ;

Tomasini, P. ;

Wislez, M. ;

Besse, B. ;

Legrain, M. ;

Voegeli, A. -C. ;

Baudrin, L. ;

Morin, F. ;

Zalcman, G. ;

Quoix, E. ;

Blons, H. ;

Cadranel, J. .

ANNALS OF ONCOLOGY, 2014, 25 (01) :126-131

[5] 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease [J].

Besse, B. ;

Adjei, A. ;

Baas, P. ;

Meldgaard, P. ;

Nicolson, M. ;

Paz-Ares, L. ;

Reck, M. ;

Smit, E. F. ;

Syrigos, K. ;

Stahel, R. ;

Felip, E. ;

Peters, S. .

ANNALS OF ONCOLOGY, 2014, 25 (08) :1475-1484

[6] Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09) [J].

Cho, Jang Ho ;

Lim, Sung Hee ;

An, Ho Jung ;

Kim, Ki Hwan ;

Park, Keon Uk ;

Kang, Eun Joo ;

Choi, Yoon Hee ;

Ahn, Mi Sun ;

Lee, Myung Hee ;

Sun, Jong-Mu ;

Lee, Se-Hoon ;

Ahn, Jin Seok ;

Park, Keunchil ;

Ahn, Myung-Ju .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)

[7] Non-Small Cell Lung Cancer, Version 1.2020 Featured Updates to the NCCN Guidelines [J].

Ettinger, David S. ;

Wood, Douglas E. ;

Aggarwal, Charu ;

Aisner, Dara L. ;

Akerley, Wallace ;

Bauman, Jessica R. ;

Bharat, Ankit ;

Bruno, Debora S. ;

Chang, Joe Y. ;

Chirieac, Lucian R. ;

D'Amico, Thomas A. ;

Dilling, Thomas J. ;

Dobelbower, Michael ;

Gettinger, Scott ;

Govindan, Ramaswamy ;

Gubens, Matthew A. ;

Hennon, Mark ;

Horn, Leora ;

Lackner, Rudy P. ;

Lanuti, Michael ;

Leal, Ticiana A. ;

Lin, Jules ;

Loo, Billy W., Jr. ;

Martins, Renato G. ;

Otterson, Gregory A. ;

Patel, Sandip P. ;

Reckamp, Karen L. ;

Riely, Gregory J. ;

Schild, Steven E. ;

Shapiro, Theresa A. ;

Stevenson, James ;

Swanson, Scott J. ;

Tauer, Kurt W. ;

Yang, Stephen C. ;

Gregory, Kristina ;

Hughes, Miranda .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (12) :1464-1472

[8] EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis [J].

Gainor, Justin F. ;

Shaw, Alice T. ;

Sequist, Lecia V. ;

Fu, Xiujun ;

Azzoli, Christopher G. ;

Piotrowska, Zofia ;

Huynh, Tiffany G. ;

Zhao, Ling ;

Fulton, Linnea ;

Schultz, Katherine R. ;

Howe, Emily ;

Farago, Anna F. ;

Sullivan, Ryan J. ;

Stone, James R. ;

Digumarthy, Subba ;

Moran, Teresa ;

Hata, Aaron N. ;

Yagi, Yukako ;

Yeap, Beow Y. ;

Engelman, Jeffrey A. ;

Mino-Kenudson, Mari .

CLINICAL CANCER RESEARCH, 2016, 22 (18) :4585-4593

[9]

GRADE Working Group, US

[10] Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study [J].

Hosomi, Yukio ;

Morita, Satoshi ;

Sugawara, Shunichi ;

Kato, Terufumi ;

Fukuhara, Tatsuro ;

Gemma, Akihiko ;

Takahashi, Kazuhisa ;

Fujita, Yuka ;

Harada, Toshiyuki ;

Minato, Koichi ;

Takamura, Kei ;

Hagiwara, Koichi ;

Kobayashi, Kunihiko ;

Nukiwa, Toshihiro ;

Inoue, Akira ;

Kudoh, S. ;

Nagao, K. ;

Nakai, Y. ;

Yoshioka, T. ;

Harada, M. ;

Isobe, T. ;

Kasai, T. ;

Oizumi, S. ;

Kamimura, M. ;

Watanabe, S. ;

Okamoto, H. ;

Shingyoji, M. ;

Osaki, Y. ;

Hasegawa, Y. ;

Koyama, S. ;

Isobe, H. ;

Morikawa, N. ;

Ishida, T. ;

Ishii, Y. ;

Takiguchi, Y. ;

Watanabe, H. ;

Kurokawa, H. ;

Sunaga, N. ;

Mori, Y. ;

Tabata, T. ;

Nakagawa, T. ;

Kuyama, S. ;

Kiura, K. ;

Usui, K. ;

Soejima, K. ;

Nishitsuji, M. ;

Kinoshita, I ;

Taima, K. ;

Nishimura, N. ;

Kishi, K. .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (02) :115-+

← 1 2 3 4 5 6 →